BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 9430472)

  • 21. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
    De Jong M; Bernard BF; De Bruin E; Van Gameren A; Bakker WH; Visser TJ; Mäcke HR; Krenning EP
    Nucl Med Commun; 1998 Mar; 19(3):283-8. PubMed ID: 9625504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
    Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
    Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reducing renal uptake of 111In-DOTATOC: a comparison among various basic amino acids.
    Lin YC; Hung GU; Luo TY; Tsai SC; Sun SS; Hsia CC; Chen SL; Lin WY
    Ann Nucl Med; 2007 Jan; 21(1):79-83. PubMed ID: 17373340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy.
    Melis M; de Swart J; de Visser M; Berndsen SC; Koelewijn S; Valkema R; Boerman OC; Krenning EP; de Jong M
    J Nucl Med; 2010 Dec; 51(12):1962-8. PubMed ID: 21078795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
    Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
    Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
    Jamar F; Barone R; Mathieu I; Walrand S; Labar D; Carlier P; de Camps J; Schran H; Chen T; Smith MC; Bouterfa H; Valkema R; Krenning EP; Kvols LK; Pauwels S
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):510-8. PubMed ID: 12582815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours.
    Smith-Jones PM; Stolz B; Albert R; Ruser G; Briner U; Mäcke HR; Bruns C
    Nucl Med Biol; 1998 Apr; 25(3):181-8. PubMed ID: 9620621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+.
    Breeman WA; De Jong MT; De Blois E; Bernard BF; De Jong M; Krenning EP
    Nucl Med Biol; 2004 Aug; 31(6):821-4. PubMed ID: 15246375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide.
    de Jong M; Barone R; Krenning E; Bernard B; Melis M; Visser T; Gekle M; Willnow TE; Walrand S; Jamar F; Pauwels S
    J Nucl Med; 2005 Oct; 46(10):1696-700. PubMed ID: 16204720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation in vitro and in rats of 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy.
    de Jong M; Breeman WA; Bernard BF; Rolleman EJ; Hofland LJ; Visser TJ; Setyono-Han B; Bakker WH; van der Pluijm ME; Krenning EP
    Eur J Nucl Med; 1995 Jul; 22(7):608-16. PubMed ID: 7498221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats.
    Rolleman EJ; Bernard BF; Breeman WA; Forrer F; de Blois E; Hoppin J; Gotthardt M; Boerman OC; Krenning EP; de Jong M
    Nuklearmedizin; 2008; 47(3):110-5. PubMed ID: 18493690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes.
    Duncan JR; Stephenson MT; Wu HP; Anderson CJ
    Cancer Res; 1997 Feb; 57(4):659-71. PubMed ID: 9044843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatobiliary handling of iodine-125-Tyr3-octreotide and indium-111-DTPA-D-Phe1-octreotide by isolated perfused rat liver.
    de Jong M; Bakker WH; Breeman WA; van der Pluijm ME; Kooij PP; Visser TJ; Docter R; Krenning EP
    J Nucl Med; 1993 Nov; 34(11):2025-30. PubMed ID: 8229254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of radioactive somatostatin and its analogues in the control of tumor growth.
    Krenning EP; Valkema R; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; de Jong M; Jamar F; Pauwels S
    Recent Results Cancer Res; 2000; 153():1-13. PubMed ID: 10626285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount.
    de Jong M; Breeman WA; Bernard BF; van Gameren A; de Bruin E; Bakker WH; van der Pluijm ME; Visser TJ; Mäcke HR; Krenning EP
    Eur J Nucl Med; 1999 Jul; 26(7):693-8. PubMed ID: 10398816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
    Bakker WH; Albert R; Bruns C; Breeman WA; Hofland LJ; Marbach P; Pless J; Pralet D; Stolz B; Koper JW
    Life Sci; 1991; 49(22):1583-91. PubMed ID: 1658515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.